
Claims

1. Compound of the following formula Ia:



(Ia)

in which

m		is 0 to 2;
n		is 0 or 1;
X		is –C(=O)-NH_2 or –COOH,
L_a		is a self-immolative linker,
A_1		is a radical of one of the amino acids Gly, Pro, Ala, Val, Nva, Leu, Ile, Met, Phe, Tyr, Trp, Ser, Thr, Cys, Asn, Gln, Asp, Glu, Lys, Arg, citrulline and His, or one of the respective N-alkyl amino acids,
A_2		is a radical of one of the amino acids D-Ala, D-Pro, D-Ser, D-Asn, D-Asp, or D-His,
R_2		is –H- or C_1-C_3-alkyl,
	or	
R_2		is the bond to the methylene group of the proline ring if A_2 is a radical which derives from D-Pro,
D		is -D_1-$(L_b)_o$-$(LIG)_p$,

D_1	is a cytotoxic drug,
LIG	is a binder which, after binding to a target molecule of a tumour cell, is internalized by the tumour cell and processed intracellularly, preferably lysosomally,
L_b	is a linker,
o and p	are each independently 0 or 1,
R	is Z_1-(C=O)q-,
q	is 0 or 1,
Z_1	is a C_{1-10}-alkyl, C_{5-10}-aryl or C_{6-10}-aralkyl, C_{5-10}-heteroalkyl, C_{1-10}-alkyl-O-C_{6-10}-aryl, C_{5-10}-heterocycloalkyl, heteroaryl, heteroarylalkyl, C_{5-10}-heteroarylalkoxy, C_{1-10}-alkoxy, C_{6-10}-aryl-C_{1-10}-alkyloxy, C_{6-10}-aryloxy or C_{6-10}-aralkoxy-, C_{5-10}-heteroalkoxy, C_{1-10}-alkyl-O-C_{6-10}-aryloxy- or C_{5-10}-heterocycloalkoxy group which may be mono- or polysubstituted by $-NH_2$, -C(=O)-, -NH-alkyl, $-N(alkyl)_2$, -NH-C(=O)-alkyl, -N(alkyl)-C(=O)-alkyl, $-S(=O)_3-H$, $-S(=O)_2-NH_2$, $-S(=O)_2-N(alkyl)_2$, -COOH, $-C(=O)NH_2$, $-C(=O)-N(alkyl)_2$ or –OH,
	or is -H or a $-(CH_2)_{0-1}$-Ox-(CH_2CH_2O)v-R^1 group,
x	is 0 or 1,
v	is a number from 1 to 20,
R^1	is –H, –alkyl, $-CH_2$-COOH, $-CH_2-CH_2$-COOH or
	$-CH_2-CH_2-NH_2$,

or

R	is LIG-$(L_c)_r$-,
LIG	is a binder which, after binding to a target molecule on a tumour cell, is internalized by the tumour cell and processed intracellularly, preferably lysosomally,

L_c is a linker and

r is 0 or 1.

2. Compound according to claim 1, where R_2 is -H or a methyl group, preferably -H.


3. Compound according to one or more of the preceding claims, where m is 1.

4. Compound according to one or more of the preceding claims, where A_1 is in the L configuration or D configuration.

5. Compound according to one or more of the preceding claims, where A_1 is the rest of the amino acid that derives from Ala or Val.

6. Compound according to one or more of the preceding claims, where q is 1, and Z_1 represents a C_{1-10}-alkyl which may be interrupted once or more than once by an oxygen atom (for example a methyl group or an optionally alkylated oligoalkylene oxide chain), C_{6-10}-aralkyl, C_{5-10}-heteroarylalkyl, C_{6-10}-aralkoxy or C_{5-10}-heteroarylalkoxy group.


7. Compound according to one or more of the preceding claims, where L_a is selected from the following groups:



where $\#_1$ represents the bond to the carbonyl group and $\#_2$ the bond to the hydroxyl or amino group of D_1.

8. Compound according to one or more of the preceding claims, where D_1 is a drug selected from mitomycin, doxorubicin, aminopterin, actinomycin, bleomycin, 9-aminocamptothecin, n8-acetylspermidine, 1-(2-chloroethyl)-1,2-dimethanesulphonyl hydrazide, tallysomycin, cytarabine, etoposide, camptothecin, taxol, esperamicin, podophyllotoxin, anguidine, vincristine, vinblastine, morpholine-doxorubicin, n-(5,5-diacetoxypentyl)doxorubicin, duocarmycin, auristatin, pyrrolobenzodiazepine derivatives, calicheamicin, daunorubicin, camptophecin DX8951 (exatecan) or a kinesin spindle protein inhibitor (KSP inhibitor), the drug being bonded via its hydroxyl or amino group to L_a (when n = 1) or the carbonyl group (when n = 0) of formula I.

9. Compound according to Claim 8, where the KSP inhibitor is a compound of the following formula (IIa):



(IIa)


in which

X_1	is N,
X_2	is N and
X_3	is C,
or	
X_1	is N,
X_2	is C and
X_3	is N,
or	
X_1	is CH or CF,
X_2	is C and

X_3	is N,
or	
X_1	is NH,
X_2	is C and
X_3	is C,
or	
X_1	is CH,
X_2	is N and
X_3	is C.

A	is –C(=O)-, -S(=O)-, -S(=O)$_2$-, or -S(=O)$_2$-NH-,
R^1	is -H, –L-#1, –MOD or -$(CH_2)_{0-3}$Z,
Z	is -H, -NHY^3, -OY^3, -SY^3, halogen, -C(=O)-NY^1Y^2, or –C(=O)-OY^3,
Y^1 and Y^2	are independently -H, -NH_2,-$(CH_2CH_2O)_{0-3}$-$(CH_2)_{0-3}$Z' or -$CH(CH_2W)$Z',
Y^3	is -H or -$(CH_2)_{0-3}$Z',
Z'	is -H, -NH_2, -$S(=O)_3H$, -COOH, -NH-C(=O)-CH_2-CH_2-$CH(NH_2)$C(=O)- or -$(C(=O)$-NH-$CHY^4)_{1-3}$COOH,
W	is -H or -OH,
Y^4	is linear or branched C_{1-6} alkyl, optionally substituted by -NH-C(=O)-NH_2, or is aryl or benzyl optionally substituted by –NH_2,
R^2	is -H, –L-#1 , -MOD, -C(=O)-CHY^4-NHY^5 or -$(CH_2)_{0-3}$Z,
Z	is -H, halogen, -OY^3, -SY^3, -NHY^3, -C(=O)-NY^1Y^2, or –C(=O)-OY^3,
Y^1 and Y^2	are independently -H, -NH_2, or -$(CH_2)_{0-3}$Z',
Y^3	is -H or -$(CH_2)_{0-3}$Z',
Z'	is -H, -$S(=O)_3H$, -NH_2 or –COOH,
Y^4	is linear or branched C_{1-6} alkyl- optionally substituted by –NHC(=O)-NH_2, or is aryl or benzyl optionally substituted by –NH_2,
Y^5	is -H or –C(=O)-CHY^6-NH_2,
Y^6	is linear or branched C_{1-6}-alkyl,

R^3	is -MOD, –L-#1, or an optionally substituted alkyl, cycloalkyl, aryl, heteroaryl, heteroalkyl, heterocycloalkyl group which may be substituted by one to three OH groups, one to three halogen atoms, one to three mono-, di- or trihalogenated alkyl groups, one to three -O-alkyl groups, one to three -SH groups, one to three -S-alkyl groups, one to three -O-C(=O)-alkyl groups, one to three -O-C(=O)-NH-alkyl groups, one to three -NH-C(=O)-alkyl groups, one to three -NH-C(=O)-NH-alkyl groups, one to three -S(=O)$_n$-alkyl groups, one to three –S(=O)$_2$-NH-alkyl groups, 1-3 -NH-alkyl groups, one to three -N(alkyl)$_2$ groups, one to three NH_2 groups or one to three -(CH$_2$)$_{0-3}$Z groups,
n	is 0, 1 or 2,
Z	is -H, halogen, -OY^3, -SY^3, -NHY^3, -C(=O)-NY^{1}Y^2 or –C(=O)-OY^3,
Y^1 and Y^2	are independently -H, -NH$_2$, or -(CH$_2$)$_{0-3}$Z',
Y^3	is -H, -(CH$_2$)$_{0-3}$-CH(NHC(=O)CH$_3$)Z',-(CH$_2$)$_{0-3}$-CH(NH$_2$)Z' or -(CH$_2$)$_{0-3}$Z',
Z'	is - H, -S(=O)$_3$H, -NH$_2$ or –C(=O)-OH,
R^4	is the legumain-cleavable group of the formulae Ia', Ia'' and Ia''',
R^5	is -H, -NH$_2$, -NO$_2$, halogen, -CN, CF$_3$, -OCF$_3$, -CH$_2$F, -CH$_2$F, -SH or -(CH$_2$)$_{0-3}$Z,
Z	is -H, -OY^3, -SY^3, halogen, -NHY^3, -C(=O)-NY^{1}Y^2, or –C(=O)-OY^3,
Y^1 and Y^2	are independently -H, -NH$_2$, or -(CH$_2$)$_{0-3}$Z',
Y^3	is -H or -(CH$_2$)$_{0-3}$Z',
Z'	is -H, -S(=O)$_3$H, -NH$_2$ or –COOH,
R^6 and R^7	are independently -H, -CN, C$_{1-10}$-alkyl, fluoro-C$_{1-10}$-alkyl, C$_{2-10}$-alkenyl, fluoro-C$_{2-10}$-alkenyl, C$_{2-10}$-alkynyl, fluoro-C$_{2-10}$-alkynyl, hydroxyl, -NO$_2$, -NH$_2$, -COOH or halogen,
R^8	is C$_{1-10}$-alkyl, fluoro-C$_{1-10}$-alkyl, C$_{2-10}$-alkenyl, fluoro-C$_{2-10}$-alkenyl,

		C_{2-10}-alkynyl, fluoro-C_{2-10}-alkynyl, C_{4-10}-cycloalkyl, fluoro-C_{4-10}-cycloalkyl or -$(CH_2)_{0-2}$-(HZ^2),
	HZ^2	is a 4- to 7-membered heterocycle having up to two heteroatoms selected from N, O and S, which may be substituted by –OH, –COOH, -NH_2 or –L-#1,
	R^9	is -H, -F, -CH_3, -CF_3, -CH_2F or -CHF_2,
	–L-#1	is -$(L_b)_o$-$(LIG)_p$,
	LIG	is a binder which, after binding to a target molecule of a tumour cell, is internalized by the tumour cell and processed intracellularly and preferably lysosomally,
	L_b	is a linker,
	o and p	are independently 0 or 1,
	–MOD	is –$(NR^{10})_n$-$(G1)_o$-G2-G3,
	R^{10}	is -H or C_1-C_3-alkyl,
	G1	is –NH-C(=O)- , -C(=O)-NH- or  ,
	n	is 0 or 1;
	o	is 0 or 1 and
	G2	is a straight-chain or branched hydrocarbon chain which has 1 to 20 carbon atoms and may be interrupted once or more than once by -O-, -S-, -S(=O)-, -$S(=O)_2$-, -NR^y-, -$NR^yC(=O)$-, -$C(=O)NR^y$-, -NR^yNR^y-, -$S(=O)_2$-NR^yNR^y-, -$C(=O)$-NR^yNR^y-, -C(=O)-, -CR^x=N-O-, and the straight-chain or branched hydrocarbon chain may be substituted by –NH-C(=O)-NH_2, -COOH, -OH, -NH_2, sulphonamide, sulphone, sulphoxide, or sulphonic acid,
	R^y	is -H, phenyl, C_1-C_{10}-alkyl, C_2-C_{10}-alkenyl or C_2-C_{10}-alkynyl, each of which may be substituted by –NH-C(=O)-NH_2, -COOH, -OH, -NH_2, sulphonamide, sulphone, sulphoxide, or sulphonic acid,
	Rx	is -H, C_1-C_3-alkyl or phenyl,
	G3	is –H or –COOH and
	–MOD	has at least one –COOH group,

and the salts, solvates and salts of the solvates thereof.

10. Compound according to Claim 9, where R^1 or R^3 is –L-#1.

11. Compound according to one or more of Claims 9 and 10, where X_1 is CH, X_2 is C and X_3 is N.

12. Compound according to one or more of Claims 9 to 11, where R^6 and R^7 are independently -H, C_{1-3}-alkyl or halogen.

13. Compound according to Claim 12, where R^6 and R^7 are F.


14. Compound according to one of more or Claims 9 to 13, where R^8 is C_{1-4}-alkyl (preferably tert-butyl) or cyclohexyl.

15. Compound according to one or more of Claims 9 to 14, where R^9 is -H.

16. Compound according to one or more of the preceding claims, where either D or R contains the binder LIG.

17. Compound according to Claim 16, where LIG is a peptide, protein or derivative thereof, selected from octreotide, GnRH-III, [D-Tyr^6, β-Ala^{11}, Phe^{13}, Nle^{14}]BN(6-14), NT(8-13), c(RGDfK), HSDAVFTDNYTRLRKQMAVKKYLNSILN-NH_2 (SEQ ID NO: 161), NAPamide, [Phe^7, Pro^{34}]NPY, HER2-targeting peptide, ATEPRKQYATPRVFWTDAPG (SEQ ID NO: 162), LQWRRDDNVHNFGVWARYRL (SEQ ID NO: 163), or an antibody or a fragment or derivative thereof which binds to an extracellular target molecule of a tumour cell and which is conjugated to further cytotoxic drugs.

18. Compounds according to one or more of the preceding claims, where the compounds have the following formula III'




III'

in which

m, n, r, LIG, L_a, L_c, D_1,
X, A_2, R_2 and A_1 have the definitions given in Claim 1.

19. Compounds of the formula IIIa'



IIIa'

in which


m, n, r, L_a, L_c,D_1, X,

R_2, A_2 and A_1 have the same definition as in Claim 1,

AB is an antibody or an antigen-binding antibody fragment and

s is 1 to 20,
preferably 2 to 8,
more preferably 2 to 6.

20. Compounds according to one or more of Claims 1 to 17, where the compounds have the following formula IV'




IV'

in which

m, n, o, R, LIG, L_a, L_b,
D_1, X, R_2, A_2 and A_1 have the same definition as in Claim 1.

21. Compounds of the formula IVa'



IVa'

in which
m, n, o, R, L_a, L_b,
D_1, X, R_2, A_2, and A_1 have the same definition as in Claim 1,
AB is an antibody or an antigen-binding antibody fragment and
s is 1 to 20,
preferably 2 to 8,
more preferably 2 to 6.

22. Compounds according to one or more of the preceding claims, where the linker L_b or L_c is bound to a cysteine side chain or a cysteine residue of a binder, for example of an antibody or an antigen-binding antibody fragment, and has the following formula:

§-(C=O)m-L1-L2-§§


where


m is 0 or 1;


§ is the bond to the drug molecule or the legumain-cleavable group and


§§ is the bond to the binder,


-L2- is the group




,



,



,



,


,



,


,


or



where

#1 denotes the linkage site to the sulphur atom of the binder,

#2 denotes the linkage site to the L^1 group,

L1 is $–(NR10)_n-(G1)_o-G2-$,


R^{10} is -H, $-NH_2$ or C_1-C_3-alkyl,





G1 is –NHC(=O)- or 

,

n is 0 or 1,

o is 0 or 1,


G2 is a straight-chain or branched hydrocarbon chain having 1 to 100 carbon atoms, composed of arylene groups and/or straight-chain and/or branched and/or cyclic alkylene groups, which may be interrupted once or more than once, by one or more of the groups -O-, -S-, -S(=O)-, -$S(=O)_2$, -NH-, -C(=O)-, -Nme-, -NHNH-, -$S(=O)_2$-NHNH-, -NH-C(=O)-, -C(=O)-NH-, -C(=O)-NHNH- and a 5- to 10-membered aromatic or nonaromatic heterocycle having up to 4 heteroatoms selected from N, O and S, -S(=O)- or –$S(=O)_2$- (preferably ), and where the side chains, if present, may be substituted by -NH-C(=O)-NH_2, -COOH, -OH, -NH_2, NH-$CNNH_2$, sulphonamide, sulphone, sulphoxide or sulphonic acid,
or one of the following groups:


, ,  or 

where

Rx is -H, C_1-C_3-alkyl or phenyl.

23. Compounds according to Claim 22, where L2 is one or both of the following formulae:





where


$\#^1$ is the linkage site to the sulphur atom of the binder,


$\#^2$ is the linkage site to the L^1 group,

R^{22} is -COOH and

the bonds to the sulphur atom of the binder are present in one of these two formulae to an extent of more than 80% (based on the total number of bonds in the linker to the binder).

24. Compounds according to Claim 22 or 23, wherein the hydrocarbon chain is interrupted by one of the following groups:






where


X is -H or a $C_{1\text{-}10}$-alkyl group which may optionally be substituted by

–NH-C(=O)-NH_2, -COOH, -OH, -NH_2, -NH-CNNH_2, sulphone, sulphoxide or sulphonic acid.

25. Compounds according to any of Claims 22 to 24, where the linker has the following formula:




in which

#3	is the bond to the drug molecule,	
#4	is the bond to the binder,	
R^{11}	is -H or -NH_2,	
B	is the –[$(CH_2)_x$-$(X^4)_y$]w-$(CH_2)_z$- group,	
w	is 0 to 20;	
x	is 0 to 5;	
y	is 0 or 1;	
z	is 0 to 5; and	
X^4	is –O-, -C(=O)-NH-,–NH-C(=O)- or	

.

26. Compounds according to one or more of the preceding claims, where the linker -L_b- and/or –L_c- is bonded to a cysteine side chain or a cysteine residue and has the following formula:



in which

§ is the bond to the drug molecule or the legumain-cleavable group,


§§ is the bond to the binder,

m is 0, 1, 2, or 3,

n is 0, 1 or 2,

p is 0 to 20,

L3 is the group




in which

o is 0 or 1,


§' is the bond to the –S(O)n group and

§" is the bond to the nitrogen atom in the ring.

G3 is a straight-chain or branched hydrocarbon chain having 1 to 100 carbon atoms, composed of arylene groups and/or straight-chain and/or branched and/or cyclic alkylene groups which may be interrupted once or more than once by one or more of the groups -O-, -S-, -S(=O)-, $S(=O)_2$-, -NH-, -C(=O)-, -NH-C(=O)-, -C(=O)-NH- and a 5- to 10-membered aromatic or nonaromatic heterocycle having up to 4 heteroatoms selected from N, O and S, -Nme-, -NHNH-, $-S(=O)_2$-NHNH-, -C(=O)-NHNH-, -S(=O)- or $-S(=O)_2$- (preferably 

), where the side chains, if present, may be substituted by –NHC(=O)-NH_2, -COOH, -OH, sulphone, sulphoxide or sulphonic acid.

27. Compounds according to Claim 26, where the linker $–L_b$- or $-L_c$- is bonded to a cysteine side chain or a cysteine residue and has the following formula:



where

§ is the bond to the drug molecule or the legumain-cleavable group,


§§ is the bond to the binder,

m is 1;

p is 0;

n is 0,

L3 is the group



in which

o is 0 or 1,

G3 is $–(CH_2CH_2O)_s - (CH_2)_t - (C(=O)-NH)_u - CH_2CH_2O)_v - (CH_2)_w-$,

s, t, v and w are independently 0 to 20,

u is 0 or 1,


§' is the bond to the –S(O)n group and

§'' is the bond to the nitrogen atom in the ring.


28. Compound according to Claim 25 or 26, where R^2 or R^3 is –L-#1.

29. Conjugates of the following structures in which:


AK	is the binder, preferably an antibody or antigen-binding antibody fragment (AK_1, AK_2, AK_3), and
AK_1	is preferably an antibody bonded to the KSP inhibitor via a cysteine residue,
AK_2	is preferably an antibody bonded to the KSP inhibitor via a lysine residue and
AK_3	is preferably an antibody bonded to the KSP inhibitor via a glutamine residue,
	and
n	is a number from 1 to 50, preferably 1 to 20, more preferably 2 to 8 and especially 2 to 6:




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




.


F
F
N
H3C
CH3
CH3
O
N
HO
O
N
H
O
OH
O
N
H
O
OH
O
NH
O
H2N
NH
H
N
O
CH3
O
CH3
O
H
N
CH3
O
N
O
AK1
n


,


F
F
N
H3C
CH3
CH3
O
N
HO
O
N
H
O
OH
O
N
H
O
OH
O
NH
O
H2N
NH
H
N
O
CH3
O
CH3
O
AK1
n

,




,




,


5




,




,




,




,



,



and



30. Compound or conjugate according to one or more of the preceding claims, wherein the antibody or the antigen-binding antibody fragment binds to an extracellular cancer target molecule.

31. Compound or conjugate according to one or more of the preceding claims, wherein the antibody or the antigen-binding antibody fragment, after binding to its extracellular target molecule on the target cell, is internalized by the target cell through the binding.

32. Compound or conjugate according to one or more of the preceding claims, wherein the antibody is an anti-HER2 antibody, an anti-EGFR antibody, an anti-B7H3 antibody, an anti-TWEAKR antibody, or an antigen-binding antibody fragment of these.

33. Compound or conjugate according to Claim 32, wherein the anti-TWEAKR antibody is selected from the group consisting of TPP-7006, TPP-7007, TPP-10336 and TPP-10337, the anti-B7H3 antibody is selected from the group

consisting of TPP-8382 and TPP-8567, the anti-EGFR antibody is cetuximab (TPP-981) and the anti-HER2 antibody is selected from the group consisting of trastuzumab and TPP-1015.

34. Compound or conjugate according to one or more of the preceding claims, wherein the antibody (AK, AB, AK1, AK2, AK3)

(i) is an anti-EGFR antibody comprising a variable region of the heavy chain (VH) comprising the variable CDR1 sequence of the heavy chain (H-CDR1), as shown by SEQ ID NO: 2, the variable CDR2 sequence of the heavy chain (H-CDR2), as shown by SEQ ID NO: 3 and the variable CDR3 sequence of the heavy chain (H-CDR3), as shown by SEQ ID NO: 4, and a variable region of the light chain (VL) comprising the variable CDR1 sequence of the light chain (L-CDR1), as shown by SEQ ID NO: 6, the variable CDR2 sequence of the light chain (L-CDR2), as shown by SEQ ID NO: 7 and the variable CDR3 sequence of the light chain (L-CDR3), as shown by SEQ ID NO: 8,

(ii) is an anti-HER2 antibody comprising a variable region of the heavy chain (VH) comprising the variable CDR1 sequence of the heavy chain (H-CDR1), as shown by SEQ ID NO: 12, the variable CDR2 sequence of the heavy chain (H-CDR2), as shown by SEQ ID NO: 13 and the variable CDR3 sequence of the heavy chain (H-CDR3), as shown by SEQ ID NO: 14, and a variable region of the light chain (VL) comprising the variable CDR1 sequence of the light chain (L-CDR1), as shown by SEQ ID NO: 16, the variable CDR2 sequence of the light chain (L-CDR2), as shown by SEQ ID NO: 17 and the variable CDR3 sequence of the light chain (L-CDR3), as shown by SEQ ID NO: 18,

(iii) is an anti-TWEAKR antibody comprising a variable region of the heavy chain (VH) comprising the variable CDR1 sequence of the heavy chain (H-CDR1), as shown by SEQ ID NO: 22, the variable CDR2 sequence of the heavy chain (H-CDR2), as shown by SEQ ID NO: 23 and the variable CDR3 sequence of the heavy chain (H-CDR3), as shown by SEQ ID NO: 24, and a variable region of the light chain (VL) comprising the variable CDR1 sequence of the light chain (L-CDR1), as shown by SEQ ID NO: 26, the variable CDR2 sequence of the light chain (L-CDR2), as shown by SEQ ID NO: 27 and the variable CDR3 sequence of the light chain (L-CDR3), as shown by SEQ ID NO: 28,

(iv) is an anti-TWEAKR antibody comprising a variable region of the heavy chain (VH) comprising the variable CDR1 sequence of the heavy chain (H-CDR1), as shown by SEQ ID NO: 32, the variable CDR2 sequence of the heavy chain (H-CDR2), as shown by SEQ ID NO: 33 and the variable CDR3 sequence of the heavy chain (H-CDR3), as shown by SEQ ID NO: 34, and a variable region of the light chain (VL) comprising the variable CDR1 sequence of the light chain (L-CDR1), as shown by SEQ ID NO: 36, the variable CDR2 sequence of the light chain (L-CDR2), as shown by SEQ ID NO: 37 and the variable CDR3 sequence of the light chain (L-CDR3), as shown by SEQ ID NO: 38,

(v) is an anti-TWEAKR antibody comprising a variable region of the heavy chain (VH) comprising the variable CDR1 sequence of the heavy chain (H-CDR1), as shown by SEQ ID NO: 42, the variable CDR2 sequence of the heavy chain (H-CDR2), as shown by SEQ ID NO: 43 and the variable CDR3 sequence of the heavy chain (H-CDR3), as shown by SEQ ID NO: 44, and a variable region of the light chain (VL) comprising the variable CDR1 sequence of the light chain (L-CDR1), as shown by SEQ ID NO: 46, the variable CDR2 sequence of the light chain (L-CDR2), as shown by SEQ ID NO: 47 and the variable CDR3 sequence of the light chain (L-CDR3), as shown by SEQ ID NO: 48,

(vi) is an anti-TWEAKR antibody comprising a variable region of the heavy chain (VH) comprising the variable CDR1 sequence of the heavy chain (H-CDR1), as shown by SEQ ID NO: 52, the variable CDR2 sequence of the heavy chain (H-CDR2), as shown by SEQ ID NO: 53 and the variable CDR3 sequence of the heavy chain (H-CDR3), as shown by SEQ ID NO: 54, and a variable region of the light chain (VL) comprising the variable CDR1 sequence of the light chain (L-CDR1), as shown by SEQ ID NO: 56, the variable CDR2 sequence of the light chain (L-CDR2), as shown by SEQ ID NO: 57 and the variable CDR3 sequence of the light chain (L-CDR3), as shown by SEQ ID NO: 58,

(vii) is an anti-TWEAKR antibody comprising a variable region of the heavy chain (VH) comprising the variable CDR1 sequence of the heavy chain (H-CDR1), as shown by SEQ ID NO: 62, the variable CDR2 sequence of the heavy chain (H-CDR2), as shown by SEQ ID NO: 63 and the variable CDR3 sequence of the heavy chain (H-CDR3), as shown by SEQ ID NO: 64, and a variable region of the light chain (VL) comprising the variable CDR1 sequence of the light chain (L-

CDR1), as shown by SEQ ID NO: 66, the variable CDR2 sequence of the light chain (L-CDR2), as shown by SEQ ID NO: 67 and the variable CDR3 sequence of the light chain (L-CDR3), as shown by SEQ ID NO: 68,

(viii) is an anti-HER2 antibody comprising a variable region of the heavy chain (VH) comprising the variable CDR1 sequence of the heavy chain (H-CDR1), as shown by SEQ ID NO: 72, the variable CDR2 sequence of the heavy chain (H-CDR2), as shown by SEQ ID NO: 73 and the variable CDR3 sequence of the heavy chain (H-CDR3), as shown by SEQ ID NO: 74, and a variable region of the light chain (VL) comprising the variable CDR1 sequence of the light chain (L-CDR1), as shown by SEQ ID NO: 76, the variable CDR2 sequence of the light chain (L-CDR2), as shown by SEQ ID NO: 77 and the variable CDR3 sequence of the light chain (L-CDR3), as shown by SEQ ID NO: 78,

(ix) is an anti-HER2 antibody comprising a variable region of the heavy chain (VH) comprising the variable CDR1 sequence of the heavy chain (H-CDR1), as shown by SEQ ID NO: 82, the variable CDR2 sequence of the heavy chain (H-CDR2), as shown by SEQ ID NO: 83 and the variable CDR3 sequence of the heavy chain (H-CDR3), as shown by SEQ ID NO: 84, and a variable region of the light chain (VL) comprising the variable CDR1 sequence of the light chain (L-CDR1), as shown by SEQ ID NO: 86, the variable CDR2 sequence of the light chain (L-CDR2), as shown by SEQ ID NO: 87 and the variable CDR3 sequence of the light chain (L-CDR3), as shown by SEQ ID NO: 88,

(x) is an anti-B7H3 antibody comprising a variable region of the heavy chain (VH) comprising the variable CDR1 sequence of the heavy chain (H-CDR1), as shown by SEQ ID NO: 92, the variable CDR2 sequence of the heavy chain (H-CDR2), as shown by SEQ ID NO: 93 and the variable CDR3 sequence of the heavy chain (H-CDR3), as shown by SEQ ID NO: 94, and a variable region of the light chain (VL) comprising the variable CDR1 sequence of the light chain (L-CDR1), as shown by SEQ ID NO: 96, the variable CDR2 sequence of the light chain (L-CDR2), as shown by SEQ ID NO: 97 and the variable CDR3 sequence of the light chain (L-CDR3), as shown by SEQ ID NO: 98,

(xi) is an anti-B7H3 antibody comprising a variable region of the heavy chain (VH) comprising the variable CDR1 sequence of the heavy chain (H-CDR1), as shown

by SEQ ID NO: 102, the variable CDR2 sequence of the heavy chain (H-CDR2), as shown by SEQ ID NO: 103 and the variable CDR3 sequence of the heavy chain (H-CDR3), as shown by SEQ ID NO: 104, and a variable region of the light chain (VL) comprising the variable CDR1 sequence of the light chain (L-CDR1), as shown by SEQ ID NO: 106, the variable CDR2 sequence of the light chain (L-CDR2), as shown by SEQ ID NO: 107 and the variable CDR3 sequence of the light chain (L-CDR3), as shown by SEQ ID NO: 108,

(xii) is an anti-TWEAKR antibody comprising a variable region of the heavy chain (VH) comprising the variable CDR1 sequence of the heavy chain (H-CDR1), as shown by SEQ ID NO: 112, the variable CDR2 sequence of the heavy chain (H-CDR2), as shown by SEQ ID NO: 113 and the variable CDR3 sequence of the heavy chain (H-CDR3), as shown by SEQ ID NO: 114, and a variable region of the light chain (VL) comprising the variable CDR1 sequence of the light chain (L-CDR1), as shown by SEQ ID NO: 116, the variable CDR2 sequence of the light chain (L-CDR2), as shown by SEQ ID NO: 117 and the variable CDR3 sequence of the light chain (L-CDR3), as shown by SEQ ID NO: 118,

(xiii) is an anti-TWEAKR antibody comprising a variable region of the heavy chain (VH) comprising the variable CDR1 sequence of the heavy chain (H-CDR1), as shown by SEQ ID NO: 122, the variable CDR2 sequence of the heavy chain (H-CDR2), as shown by SEQ ID NO: 123 and the variable CDR3 sequence of the heavy chain (H-CDR3), as shown by SEQ ID NO: 124, and a variable region of the light chain (VL) comprising the variable CDR1 sequence of the light chain (L-CDR1), as shown by SEQ ID NO: 126, the variable CDR2 sequence of the light chain (L-CDR2), as shown by SEQ ID NO: 127 and the variable CDR3 sequence of the light chain (L-CDR3), as shown by SEQ ID NO: 128,

(xiv) is an anti-TWEAKR antibody comprising a variable region of the heavy chain (VH) comprising the variable CDR1 sequence of the heavy chain (H-CDR1), as shown by SEQ ID NO: 132, the variable CDR2 sequence of the heavy chain (H-CDR2), as shown by SEQ ID NO: 133 and the variable CDR3 sequence of the heavy chain (H-CDR3), as shown by SEQ ID NO: 134, and a variable region of the light chain (VL) comprising the variable CDR1 sequence of the light chain (L-CDR1), as shown by SEQ ID NO: 136, the variable CDR2 sequence of the light

chain (L-CDR2), as shown by SEQ ID NO: 137 and the variable CDR3 sequence of the light chain (L-CDR3), as shown by SEQ ID NO: 138,

(xv) is an anti-TWEAKR antibody comprising a variable region of the heavy chain (VH) comprising the variable CDR1 sequence of the heavy chain (H-CDR1), as shown by SEQ ID NO: 142, the variable CDR2 sequence of the heavy chain (H-CDR2), as shown by SEQ ID NO: 143 and the variable CDR3 sequence of the heavy chain (H-CDR3), as shown by SEQ ID NO: 144, and a variable region of the light chain (VL) comprising the variable CDR1 sequence of the light chain (L-CDR1), as shown by SEQ ID NO: 146, the variable CDR2 sequence of the light chain (L-CDR2), as shown by SEQ ID NO: 147 and the variable CDR3 sequence of the light chain (L-CDR3), as shown by SEQ ID NO: 148, or

(xvi) is an anti-TWEAKR antibody comprising a variable region of the heavy chain (VH) comprising the variable CDR1 sequence of the heavy chain (H-CDR1), as shown by SEQ ID NO: 152, the variable CDR2 sequence of the heavy chain (H-CDR2), as shown by SEQ ID NO: 153 and the variable CDR3 sequence of the heavy chain (H-CDR3), as shown by SEQ ID NO: 154, and a variable region of the light chain (VL) comprising the variable CDR1 sequence of the light chain (L-CDR1), as shown by SEQ ID NO: 156, the variable CDR2 sequence of the light chain (L-CDR2), as shown by SEQ ID NO: 157 and the variable CDR3 sequence of the light chain (L-CDR3), as shown by SEQ ID NO: 158,

or is an antigen-binding fragment of these antibodies.

35. Compound or conjugate according to one or more of the preceding claims, wherein the antibody (AK, AB, AK1, AK2, AK3)

(i) is an anti-EGFR antibody comprising a variable region of the heavy chain (VH) corresponding to SEQ ID NO: 1 and a variable region of the light chain (VL) corresponding to SEQ ID NO: 5,

(ii) is an anti-HER2 antibody comprising a variable region of the heavy chain (VH) corresponding to SEQ ID NO: 11 and a variable region of the light chain (VL) corresponding to SEQ ID NO: 15,

(iii) is an anti-TWEAKR antibody comprising a variable region of the heavy chain (VH) corresponding to SEQ ID NO: 21 and a variable region of the light chain (VL) corresponding to SEQ ID NO: 25,

(iv) is an anti-TWEAKR antibody comprising a variable region of the heavy chain (VH) corresponding to SEQ ID NO: 31 and a variable region of the light chain (VL) corresponding to SEQ ID NO: 35,

(v) is an anti-TWEAKR antibody comprising a variable region of the heavy chain (VH) corresponding to SEQ ID NO: 41 and a variable region of the light chain (VL) corresponding to SEQ ID NO: 45,

(vi) is an anti-TWEAKR antibody comprising a variable region of the heavy chain (VH) corresponding to SEQ ID NO: 51 and a variable region of the light chain (VL) corresponding to SEQ ID NO: 55,

(vii) is an anti-TWEAKR antibody comprising a variable region of the heavy chain (VH) corresponding to SEQ ID NO: 61 and a variable region of the light chain (VL) corresponding to SEQ ID NO: 65,

(viii) is an anti-HER2 antibody comprising a variable region of the heavy chain (VH) corresponding to SEQ ID NO: 71 and a variable region of the light chain (VL) corresponding to SEQ ID NO: 75,

(ix) is an anti-HER2 antibody comprising a variable region of the heavy chain (VH) corresponding to SEQ ID NO: 81 and a variable region of the light chain (VL) corresponding to SEQ ID NO: 85,

(x) is an anti-B7H3 antibody comprising a variable region of the heavy chain (VH) corresponding to SEQ ID NO: 91 and a variable region of the light chain (VL) corresponding to SEQ ID NO: 95,

(xi) is an anti-B7H3 antibody comprising a variable region of the heavy chain (VH) corresponding to SEQ ID NO: 101 and a variable region of the light chain (VL) corresponding to SEQ ID NO: 105,

(xii) is an anti-TWEAKR antibody comprising a variable region of the heavy chain (VH) corresponding to SEQ ID NO: 111 and a variable region of the light chain (VL) corresponding to SEQ ID NO: 115,

(xiii) is an anti-TWEAKR antibody comprising a variable region of the heavy chain (VH) corresponding to SEQ ID NO: 121 and a variable region of the light chain (VL) corresponding to SEQ ID NO: 125,

(xiv) is an anti-TWEAKR antibody comprising a variable region of the heavy chain (VH) corresponding to SEQ ID NO: 131 and a variable region of the light chain (VL) corresponding to SEQ ID NO: 135,

(xv) is an anti-TWEAKR antibody comprising a variable region of the heavy chain (VH) corresponding to SEQ ID NO: 141 and a variable region of the light chain (VL) corresponding to SEQ ID NO: 145, or

(xvi) is an anti-TWEAKR antibody comprising a variable region of the heavy chain (VH) corresponding to SEQ ID NO: 151 and a variable region of the light chain (VL) corresponding to SEQ ID NO: 155,

or is an antigen-binding fragment of these antibodies.

36. Compound or conjugate according to one or more of the preceding claims, wherein the antibody (AK, AB, AK1, AK2, AK3)

(i) is an anti-EGFR antibody comprising a region of the heavy chain corresponding to SEQ ID NO: 9 and a region of the light chain corresponding to SEQ ID NO: 10,

(ii) is an anti-HER2 antibody comprising a region of the heavy chain corresponding to SEQ ID NO: 19 and a region of the light chain corresponding to SEQ ID NO: 20,

(iii) is an anti-TWEAKR antibody comprising a region of the heavy chain corresponding to SEQ ID NO: 29 and a region of the light chain corresponding to SEQ ID NO: 30,

(iv) is an anti-TWEAKR antibody comprising a region of the heavy chain corresponding to SEQ ID NO: 39 and a region of the light chain corresponding to SEQ ID NO: 40,

(v) is an anti-TWEAKR antibody comprising a region of the heavy chain corresponding to SEQ ID NO: 49 and a region of the light chain corresponding to SEQ ID NO: 50,

(vi) is an anti-TWEAKR antibody comprising a region of the heavy chain corresponding to SEQ ID NO: 59 and a region of the light chain corresponding to SEQ ID NO: 60,

(vii) is an anti-TWEAKR antibody comprising a region of the heavy chain corresponding to SEQ ID NO: 69 and a region of the light chain corresponding to SEQ ID NO: 70,

(viii) is an anti-HER2 antibody comprising a region of the heavy chain corresponding to SEQ ID NO: 79 and a region of the light chain corresponding to SEQ ID NO: 80,

(ix) is an anti-HER2 antibody comprising a region of the heavy chain corresponding to SEQ ID NO: 89 and a region of the light chain corresponding to SEQ ID NO: 90,

(x) is an anti-B7H3 antibody comprising a region of the heavy chain corresponding to SEQ ID NO: 99 and a region of the light chain corresponding to SEQ ID NO: 100,

(xi) is an anti-B7H3 antibody comprising a region of the heavy chain corresponding to SEQ ID NO: 109 and a region of the light chain corresponding to SEQ ID NO: 110,

(xii) is an anti-TWEAKR antibody comprising a region of the heavy chain corresponding to SEQ ID NO: 119 and a region of the light chain corresponding to SEQ ID NO: 120,

(xiii) is an anti-TWEAKR antibody comprising a region of the heavy chain corresponding to SEQ ID NO: 129 and a region of the light chain corresponding to SEQ ID NO: 130,

(xiv) is an anti-TWEAKR antibody comprising a region of the heavy chain corresponding to SEQ ID NO: 139 and a region of the light chain corresponding to SEQ ID NO: 140,

(xv) is an anti-TWEAKR antibody comprising a region of the heavy chain corresponding to SEQ ID NO: 149 and a region of the light chain corresponding to SEQ ID NO: 150, or

(xvi) is an anti-TWEAKR antibody comprising a region of the heavy chain corresponding to SEQ ID NO: 159 and a region of the light chain corresponding to SEQ ID NO: 160,

or is an antigen-binding fragment of these antibodies.

37. Pharmaceutical composition comprising a compound according to one or more of the preceding claims in combination with an inert non-toxic pharmaceutically suitable excipient.

38. Compound according to one or more of the preceding claims for use in a method for treatment and/or prophylaxis of diseases.

39. Use of a compound according to one or more of the preceding claims in the manufacture of a medicament for the treatment of hyperproliferative and/or angiogenic disorders.